Why the study?
Do different pharmacological properties of beta-blockers (cardioselectivity, partial agonism, alpha-blockade) affect the prevention of airflow obstruction in normal subjects?
Do different pharmacological properties of beta-blockers (cardioselectivity, partial agonism, alpha-blockade) affect the prevention of airflow obstruction in normal subjects?
The cardioselectivity of beta-blockers may be lost at higher oral doses used for angina and hypertension, making partial agonism or alpha-blocking activity more relevant for preventing airflow obstruction.
Answers are grounded in this paper and cite their sources.
Higher oral doses may increase bronchospasm risk in susceptible patients; leaves open the dominant role of partial agonism or alpha-blockade.
SummaryMost of the beta-adrenoceptor blocking drugs in current use possess other pharmacological actions at certain concentrations. These include membrane stabilizing,3-8 partial agonist,12'9 and alpha-adrenoceptor blocking10 actions, and cardioselectivity.4 7 We have investigated the relative importance of partial agonist activity and cardioselectivity of several beta-adrenoceptor blocking drugs in normal subjects using the method of Kumana, Marlin and Kaye,6 in which beta-adrenoceptor activity is increased by a standardized exercise procedure. Our preliminary evidence suggests that while cardioselectivity can be shown for drugs such as practolol and metoprolol in appropriate low intravenous doses, this may be lost with the higher doses given orally for angina pectoris and hypertension, when partial agonism or alpha-adrenoceptor blocking activity, or both, may prove to be more important in preventing airflow obstruction.
No takes yet. Share an insight, caveat, or question.
Oh et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: